Finance

Beta
Lists
000538:SHE
Yunnan Baiyao Group Co Ltd
CN¥48.81
+0.43%
(+0.21) 1D
Jun 5, 3:04:12 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 000538...
Open
CN¥48.60
High
CN¥49.48
Low
CN¥48.60
Mkt. cap
87.70B
Avg. vol.
8.73M
Volume
9.41M
Dividend
5.33%
Quarterly dividend
CN¥0.65
Ex-dividend date
Apr 30, 2026
P/E ratio
16.57
52-wk high
CN¥60.69
52-wk low
CN¥48.02
EPS
CN¥2.95
Shares outstanding
1.78B
No. of employees
9K
Open
CN¥48.60
High
CN¥49.48
Low
CN¥48.60
Mkt. cap
87.70B
Avg. vol.
8.73M
Volume
9.41M
Dividend
5.33%
Quarterly dividend
CN¥0.65
Ex-dividend date
Apr 30, 2026
P/E ratio
16.57
52-wk high
CN¥60.69
52-wk low
CN¥48.02
EPS
CN¥2.95
Shares outstanding
1.78B
No. of employees
9K
News stories
From sources across the web
Profile
Yunnan Baiyao Group Co., Ltd is a Chinese pharmaceutical company that develops and manufactures pharmaceutical products and the wholesale and retail of pharmaceutical products. The Government Pension Fund of Norway has excluded the company from investments since 21 December 2021, since the company "uses and sells body parts from pangolins which is a globally endangered species". As of 2024, state and individual investors hold 29% of the shares and private companies hold 35%. The three largest shareholders hold 58 per cent of the company's shares. Wikipedia
About Yunnan Baiyao Group Co Ltd
CEO-
Employees9.29K
Founded1902
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
10.42B
9.40B
10.53B
11.60B
Cost of goods sold
7.32B
6.70B
7.85B
8.05B
Cost of revenue
7.32B
6.70B
7.85B
8.05B
Research and development expenses
95.78M
79.10M
115.55M
76.79M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.65B
1.39B
2.37B
1.28B
Operating expense
1.86B
1.33B
2.67B
1.44B
Total operating expenses
9.18B
8.03B
10.52B
9.48B
Operating income
1.23B
1.37B
12.79M
2.12B
Other non operating income
37.37M
-43.28M
135.88M
-17.44M
EBT including unusual items
1.98B
1.38B
428.17M
2.36B
EBT excluding unusual items
1.90B
1.47B
233.79M
2.35B
Income tax expense
258.80M
238.66M
27.40M
330.30M
Effective tax rate
13.10%
17.25%
6.40%
13.99%
Other operating expenses
71.80M
-18.86M
129.96M
6.54M
Net income
1.70B
1.14B
376.37M
2.04B
Net profit margin
16.30%
12.18%
3.57%
17.56%
Earnings per share
0.88
0.61
0.18
1.10
Interest and investment income
646.45M
136.98M
107.27M
253.40M
Interest expense
-4.63M
-4.39M
-8.83M
-5.09M
Net interest expenses
641.81M
132.58M
98.43M
248.31M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.29B
1.42B
70.91M
2.18B
Gain or loss from assets sale
-2.26M
2.26M
-8.17M
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more